Anders has over thirty-five years of work experience from conducting research in academic and pharmaceutical R&D settings. He was main responsible for driving the establishment, strategic directions and continuous development of an AstraZeneca internal unit which supported the internal R&D organisation with the type of histopathological analyses Offspring Biosciences now are offering to the wider scientific community. Anders has solid leadership and scientific skills acquired as academic research group leader and as team leader, project leader, department representative in project core teams and as member in line group management teams within the pharmaceutical industry.
COO and Chairman of the Board
Dan has over 30 years of experience working with techniques of direct relevance to our company’s service portfolio. He was main responsible for the establishment of a platform for histology-based target validation in neurology at AstraZeneca R&D, Södertälje. This included the build of a bank of animal and human tissues representing various neurological disorders as well as coordinating target validation studies from early pre-clinical phase to clinical trials in phase I. He has worked as department-representative in several drug development projects where he coordinated cross-functional activities across research and therapy areas, reporting to multiple customers and stakeholders. Dan has in-depth understanding of the drug development process in preclinical and early clinical phases and good knowledge of both small and large molecular drug pharmacology.
HR and Finance Manager
Anne has over thirty years of working experience with techniques of direct relevance to the services offered by Offspring Biosciences. Mainly operative and lab-based responsibilities, including development, refinements and problem solving of scientific imaging technologies. Study planning, execution, interpretation and reporting. Delivering histology, immunohistochemistry, receptor autoradiography and in situ hybridization histochemistry-based analyses in local drug discovery projects.
Helen Jongsma Wallin
Lead Project Coordinator
Helen has over 15 years of experience working with techniques relevant to the services offered by Offspring Biosciences. This includes solid skills from work in academic and pharmaceutical industry settings to develop, refine and apply technologies used to address questions in in vivo pharmacology and in vitro imaging studies. At Offspring, Helen is responsible as lead on some of our customer studies, from design/planning and execution to interpretation and reporting. At AstraZeneca, Helen functioned as department-representative in several drug development projects where she coordinated in vivo pharmacology activities and reported to multiple customers and stakeholders.
Mia has over twenty years of working experience with techniques relevant to services offered by Offspring Biosciences. She has worked both in academia, pharmaceutical -, cosmetic - and biotech industry. At Offspring Biosciences Mia is responsible as a functional project leader from design/planning and execution to interpretation and reporting of different studies.
Non Executive Director
Currently Chief Executive Officer of Histopath Consulting Ltd, and previously Managing Director and owner of Histologix Ltd, which he took from startup through to sale, has been involved in a range of global research and regulatory projects including, but not limited to, immuno-oncology, in situ hybridization, antibody multiplexing, immunohistochemistry assay validation, image analysis and biosimilars, and as a result is able to advise on a range of technical issues. He has a wealth of knowledge and experience gained from within the contract research regulatory environment over many years and has been technically and commercially responsible for developing and running specialised histology studies for the pharmaceutical and biotechnology industry.
Non Executive Director
Alan is Chief Executive at Talk Biotech Ltd, where he provides a range of life sciences research products and services, and commercial consulting services including support for technology and biotechnology startups, small to medium enterprises and university spinouts. He has over 20 years of experience in the life sciences industry, including working within an FDA audited GLP-compliant lab, several commercial roles for a blue-chip global technology company, and senior commercial roles at contract research organizations